In addition, all β-lactam antibiotics activated the GLT-1 promoter and protein expression in vivo, and CEF pretreatment was protective in two different models, delayed disease onset and loss of muscle strength, and increased survival in ALS mice (Rothstein et al., 2005). The gene discussed is SLC1A2; the disease is amyotrophic lateral sclerosis.